Niccolò Bartalucci

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Ayalew Tefferi, Paola Guglielmelli, Maura Nicolosi et al. · Leukemia · 2018 · 294 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi et al. · Blood · 2011 · 149 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Co‐targeting the PI3K/ <scp>mTOR</scp> and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms

Niccolò Bartalucci, Lorenzo Tozzi, Costanza Bogani et al. · Journal of Cellular and Molecular Medicine · 2013 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

Costanza Bogani, Niccolò Bartalucci, Serena Martinelli et al. · PLoS ONE · 2013 · 106 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

A.M. Vannucchi, Giada Rotunno, Niccolò Bartalucci et al. · Leukemia · 2014 · 83 citations · Full text

Medicine, Hematology, Pathology +11